SCHEMBL2003190

SCHEMBL2003190

COC(=O)c1cncc(C)c1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.50
ALDH1A1 P00352 6/20 0.50
GAA P10253 4/20 0.50
GLA P06280 3/20 0.50
TSHR P16473 1/20 0.47
ATM Q13315 2/20 0.44
HSD17B10 Q99714 3/20 0.43
CFTR P13569 1/20 0.43
ACHE P22303 4/20 0.42
POLB P06746 1/20 0.41
HPGD P15428 3/20 0.40
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
MAPT P10636 1/20 0.40
PTGER4 P35408 1/20 0.39
HTT P42858 1/20 0.39
NCOA1 Q15788 1/20 0.39
RCE1 Q9Y256 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30573060 1.00 KDM4E (0.50) KDM4EALDH1A1GAAGLATSHR
SCHEMBL3913326 0.82 ALDH1A1 (0.53) KDM4EALDH1A1GAATSHRHSD17B10
SCHEMBL31214158 0.81 ATM (0.47) KDM4EALDH1A1GAAGLATSHR
SCHEMBL30573103 0.80 KDM4E (0.49) KDM4EALDH1A1GAAGLATSHR
SCHEMBL17603665 0.80 KDM4E (0.49) KDM4EALDH1A1GAAGLATSHR
SCHEMBL2003114 0.79 KDM4E (0.52) KDM4EALDH1A1HSD17B10HPGDCASP7
SCHEMBL30573034 0.79 KDM4E (0.52) KDM4EALDH1A1HSD17B10HPGDCASP7
SCHEMBL2005686 0.78 SIRT3 (0.38) KDM4EGAACASP1SIRT3TDP1
SCHEMBL21558450 0.78 ATM (0.44) KDM4EALDH1A1GAAGLATSHR
SCHEMBL2014672 0.78 KDM4E (0.59) KDM4EALDH1A1GAAGLATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
EP-3237414-B1 FUSED PYRIMIDINE COMPOUNDS FOR THE TRATMENT OF HIV GILEAD SCIENCES INC (US) 2019-05-08 EP disclosed
US-7960394-B2 3,8-dimethyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]-4(3H)-quinazolinone; 6-chloro-3-methyl-2-[4-(3-piperidin-1-ylpropoxy)phenyl]pyrido[3,4-d]-pyrimidin-4(3H)-one; 2-[4-(1-cyclopentyl-4-piperidinyloxy)phenyl]-3-methylpyrido[2,3-d]-pyrimidin-4(3H)-one; treats metabolic, nervous system, vascular disorders BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-06-14 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
CN-1960977-A Quinazoline derivative BANYU PHARMA CO LTD (JP) 2007-05-09 CN disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 KDM4E 3385/4885ALDH1A1 2782/4885GAA 1869/4885
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 KDM4E 4346/4885ALDH1A1 1762/4885GAA 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.